

1 Title:

2 Circulating CD4+ T cells in people with HIV and history of pulmonary tuberculosis have more  
3 intact HIV DNA

4

5 Marc Antoine Jean Juste<sup>1\*</sup>, Yvetot Joseph<sup>1\*</sup>, Dominique Lespinasse<sup>1</sup>, Alexandra Apollon<sup>1</sup>,  
6 Parmida Jamshidi<sup>2</sup>, Myung Hee Lee<sup>2</sup>, Maureen Ward<sup>2</sup>, Esther Brill<sup>2</sup>, Yanique Duffus<sup>2</sup>, Uche  
7 Chukwukere<sup>2</sup>, Ali Danesh<sup>2</sup>, Winiffer Conce Alberto<sup>2</sup>, Daniel W. Fitzgerald<sup>2</sup>, Jean W. Pape<sup>1,2</sup>, R.  
8 Brad Jones<sup>2</sup>, Kathryn Dupnik<sup>2</sup>

9

10 <sup>1</sup> GHESKIO Centers, Port au Prince, Haiti

11 <sup>2</sup> Department of Medicine, Weill Cornell Medicine, New York, NY 10021

12

13 \* There are two co-first authors. Dr. Jean Juste is listed first because the pilot cohort for which  
14 he supervised enrollment contributed a larger number of participants to this study.

15

16

17 Corresponding author:

18 Kathryn M. Dupnik

19 Weill Cornell Medicine Center for Global Health

20 402 E 67<sup>th</sup> Street, 2<sup>nd</sup> floor

21 New York NY 10065

22 Phone: 646-962-8140

23 Email: kad9040@med.cornell.edu

24

25 Conflict of interest statement:

26 The authors have declared that no conflict of interest exists.

27 ABSTRACT

28

29 Background: The primary barrier to curing HIV infection is the pool of intact HIV proviruses  
30 integrated into host cell DNA throughout the bodies of people living with HIV (PLHIV), called the  
31 HIV reservoir. Reservoir size is impacted by the duration of HIV infection, delay in starting  
32 antiretroviral therapy (ART), and breakthrough viremia during ART. The leading infectious cause  
33 of death worldwide for PLHIV is TB, but we don't know how TB impacts the HIV reservoir.

34 Methods: We designed a case-control study to compare HIV provirus-containing CD4 in PLHIV  
35 with vs. without a history of active TB disease. Study participants in the pilot and confirmatory  
36 cohort were enrolled at GHESKIO Centers in Port au Prince, Haiti. Intact and non-intact proviral  
37 DNA were quantified using droplet digital PCR of PBMC-derived CD4 cells. For a subset, Th1  
38 and Th2 cytokines were assayed in plasma. Kruskal-Wallis tests were used to compare medians  
39 with tobit regression for censoring.

40 Results: In the pilot cohort, we found that PLHIV with history of active pulmonary TB (n=20) had  
41 higher intact provirus than PLHIV without history of active TB (n=47) (794 vs 117 copies per million  
42 CD4, respectively;  $p < 0.0001$ ). In the confirmatory cohort, the quantity of intact provirus was higher  
43 in the TB group (n=13) compared with the non-TB group (n=18) (median 102 vs. 0 intact provirus  
44 per million CD4, respectively  $p = 0.03$ ). Additionally, we found that the frequencies of CD4+ T cells  
45 with any detectable proviral fragment was directly proportional to the levels of IL1B ( $p = 0.0025$ )  
46 and IL2 ( $p = 0.0002$ ).

47 Conclusions. This is the first assessment of HIV provirus using IPDA in a clinical cohort from a  
48 resource limited setting, and the finding of larger reservoir in PLHIV with history of TB has  
49 significant implications for our understanding of TB-HIV coinfection and HIV cure efforts in TB-  
50 endemic settings.

---

51

52 MANUSCRIPT

53

54 The primary barrier to curing HIV infection is the pool of intact HIV proviruses integrated into host  
55 cell DNA throughout the bodies of people living with HIV (PLHIV), called the HIV reservoir.  
56 Reservoir size is impacted by the duration of HIV infection, delay in starting antiretroviral therapy  
57 (ART), and breakthrough viremia during ART. Increased reservoir size has been associated with  
58 worse clinical outcomes, including neurocognitive impairment (1). The leading infectious cause of  
59 death worldwide for PLHIV is TB, but we don't know how TB impacts the HIV reservoir. An  
60 approximation of reservoir size can be attained by quantitative PCR of HIV DNA in peripheral  
61 blood mononuclear cells (PBMC). One group used this approach to study HIV DNA levels in  
62 PBMCs from PLHIV with and without active pulmonary TB in Uganda and did not see a statistically  
63 significant difference (2). However, in a cohort in China, PLHIV with history of TB had a higher  
64 level of circulating HIV DNA than people without TB, but they also had higher viral load pre-ART  
65 (3). People with TB-HIV coinfection may have increased risk of virological failure and  
66 breakthrough viremias, resulting from or contributing to greater quantities of HIV DNA in  
67 circulating CD4+ T cells.

68

69 The emerging gold standard for the measurement of HIV reservoirs is the intact proviral DNA  
70 assay (IPDA), which distinguishes intact from defective proviruses, the latter being much more  
71 numerous (4). We applied a modified IPDA (5) to a cohort of people with HIV in a resource-limited  
72 setting with a TB syndemic to determine how quantities of CD4+ T cells containing HIV provirus  
73 vary in people who had had active bacteriologically confirmed pulmonary TB disease concurrent  
74 with or after diagnosis of HIV.

75

76 Using IPDA (*see supplemental methods*), we measured proviral loads for 100 PLHIV participating  
77 in a TB study at GHESKIO Centers in Port au Prince, Haiti, 50 people with active or history of

78 bacteriologically confirmed pulmonary TB and 50 people with no history of TB (Supplemental  
79 Table 1). Within the total cohort, there was a nearly 8-fold difference in intact provirus levels  
80 between current or history of TB vs. no TB (median 881 vs 116 copies per million CD4+ T cells,  
81 respectively;  $p=0.0001$ ) (Figure 1A). Tobit regression of detectable intact provirus also showed  
82 statistically significant difference in intact provirus ( $p < 0.0001$ ) between the TB and non-TB  
83 groups. There was no statistically significant difference in intact provirus between people with  
84 newly diagnosed untreated TB ( $n=25$ ) vs. history of TB or TB currently being treated ( $n=25$ )  
85 (median 897 vs. 865 copies per million CD4+ T cells, respectively;  $p=0.92$ ; Supplemental Figure  
86 1A). In the people with no history of TB, the amount of intact provirus in CD4+ T cells was not  
87 statistically significantly different by IGRA status (median 80 for IGRA-positive vs. 118 for IGRA-  
88 negative per million CD4,  $p=0.65$ ; Supplemental Figure 1B).

89  
90 To remove potential confounders of the difference in intact provirus observed in the initial groups,  
91 we excluded 26 people with HIV diagnosed less than one year before sample collection. We  
92 excluded 3 people with no plasma available for p24 testing and 3 people with detectable plasma  
93 p24. One person who had TB prior to HIV diagnosis was also excluded. After these adjustments,  
94 the difference in intact proviral load between TB and no-TB groups remained statistically  
95 significant (median 794 vs 117 copies per million CD4, respectively;  $p=0.0001$ ) by Kruskal-Wallis  
96 test as well as by tobit regression ( $p<0.0001$ ). This difference remained statistically significant  
97 when analyzing women and men independently ( $p< 0.005$ ).

98  
99 For the confirmatory study, we began with 34 participants from a study of TB recurrence. One  
100 participant's PBMC did not have enough live cells after thawing to have CD4+ T cells selected  
101 and DNA extracted so was excluded from downstream analyses. One DNA sample failed QC with  
102 no detectable intact, *env* fragment, or *psi* fragment with all tested primer sets and so was  
103 excluded. One person had HIV viral load  $> 1,000$  copies/mL as well as detectable p24 after

104 dissociation. This person was excluded as the high-level viremia could have rendered the IPDA  
105 quantitation inaccurate. In the final analysis group from the confirmatory cohort (Supplemental  
106 Table 2), the quantity of intact provirus was higher in the TB group compared with the non-TB  
107 group (median 102 vs. 0 intact provirus per million CD4, respectively  $p=0.03$ ) (Figure 1B). We  
108 also analyzed the intact provirus levels using a tobit regression model with 12 left-censored  
109 observations for intact proviral loads less than the lower limit of detection and the difference  
110 remained statistically significant ( $p=0.04$ ). In the participants with no history of TB, there wasn't a  
111 statistically significant difference in intact proviral load with IGRA positivity (median 0 vs 9 intact  
112 provirus per million CD4,  $p=0.96$ ; Supplemental Figure 2A). In participants with history of one or  
113 recurrent episodes of TB, there was no statistically significant difference in intact proviral load in  
114 CD4+ T cells (median 103 vs 103 intact provirus per million CD4,  $p=0.55$ ; Supplemental Figure  
115 2B).

116  
117 Additionally, we found that the frequencies of CD4+ T cells with any detectable proviral fragment  
118 was directly proportional to the levels of IL1B (0.0025, Figure 1C), IL2 ( $p=0.0002$ , Figure 1D),  
119 IL12p70 ( $p=0.0093$ ), and IL13 ( $p=0.0067$ ). After Bonferroni correction for the 8 analyzable  
120 cytokines, (cutoff  $p_{adj}=0.05/8=0.006$ ), the association between plasma IL-1B and IL2 and CD4  
121 containing HIV *gag* or *pol* remained statistically significant. The difference in IL1B and IL2 levels  
122 between the TB and no-TB groups was not statistically significant ( $p=0.08$  and  $p=0.1$ ,  
123 respectively), but by observation of the fit lines for the cytokine levels by proviral load, the levels  
124 were overall higher for the TB group than for the non-TB group (Figure 1C and 1D).

125  
126 In our pilot and confirmatory cohorts, we documented significantly higher levels of intact HIV  
127 proviruses in circulating CD4+ T cells of PLHIV with histories of bacteriologically confirmed  
128 pulmonary TB. Levels of HIV DNA correlated directly with levels of the pro-inflammatory cytokines  
129 IL1B and IL2 with a trend to higher levels in people with a history of TB. Strengths of the study

130 include the use of IPDA to discriminate intact versus defective HIV proviruses, translational  
131 approach using samples from people who have experienced the true natural history of HIV-TB  
132 coinfection, and confirmatory cohort testing. Limitations include incomplete CD4+ T cell count  
133 nadir data because of the changing landscape of CD4 testing in HIV care, inclusion of only  
134 bacteriologically confirmed pulmonary TB, and HIV proviral load testing at only a single time point.  
135 This is the first assessment of HIV provirus using IPDA in a clinical cohort from a resource limited  
136 setting, and the finding of 8-fold larger reservoir in PLHIV with history of TB has significant  
137 implications for our understanding of TB-HIV coinfection and HIV cure efforts in TB-endemic  
138 settings.

139

140 PLHIV with TB exhibit systemic inflammation and immune activation. Local inflammation has the  
141 propensity to increase HIV replication and viral load at sites where HIV and replicating Mtb exist,  
142 even prior to the development of symptomatic TB (6). Mtb cell wall components are able to  
143 activate TLR signaling to induce HIV replication without live bacteria and may induce HIV  
144 transcription in neighboring cells that are uninfected with Mtb (6). These factors may contribute to  
145 the larger HIV reservoir in PLHIV with history of pulmonary TB, and should make TB a serious  
146 consideration for all reservoir-targeting HIV cure endeavors.

---

147

148 Supplemental Information

149 **1. Supplemental materials and methods**

150 Sex as a biological variable. This study included men and women. A post-hoc analysis with  
151 stratification by sex was performed which showed similar findings of statistically significantly  
152 higher percentage of CD4+ T cells containing intact provirus in people with history of pulmonary  
153 TB.

154

155 Study site. The prevalence of HIV in adults in Haiti was 1.8% in 2021 . Haiti has the highest rate  
156 of TB in the Americas with 154 new cases of TB per 100,000 people in 2022, of whom 15% were  
157 HIV-positive (7). GHESKIO centers in Port au Prince, Haiti is a Haitian non-profit organization that  
158 is the largest provider of HIV and TB care in the Americas.

159

160 Clinical cohorts

161 For the pilot study, people with microbiologically confirmed pulmonary TB were enrolled from TB  
162 ambulatory care centers at GHESKIO as part of a study on tuberculosis. People living with HIV  
163 with or without history of TB were enrolled from the TB and HIV clinics at GHESKIO. Latent TB  
164 testing was using the Quantiferon-TB Gold In-Tube interferon-gamma release assay (IGRA)  
165 (Qiagen, MD, USA). Blood for peripheral blood mononuclear cell (PBMC) isolation was collected  
166 with heparin as an anticoagulant. The pilot nested case-control study included people with new  
167 diagnosis of bacteriologically confirmed pulmonary TB, people with history of bacteriologically  
168 confirmed pulmonary TB, and people with no history of TB who were either IGRA positive or IGRA  
169 negative.

170

171 For the confirmatory study, volunteer participants were enrolled in a study of the human immune  
172 response to TB with an emphasis on recurrent TB at GHESKIO. Participants had HIV and were  
173 receiving suppressive ART with a history of zero, one, or two episodes of TB after HIV diagnosis.

174 They had one study visit with questionnaire, demographics, and phlebotomy. Latent TB testing  
175 was using the Quantiferon-TB Gold Plus In-Tube interferon-gamma release assay (IGRA)  
176 (Qiagen, MD, USA). Blood for peripheral blood mononuclear cell (PBMC) isolation was collected  
177 with EDTA as an anticoagulant.

178

179 For both studies, PBMC were isolated at GHESKIO using density gradient separation (Ficoll-  
180 Hypaque, GE Healthcare) with  $5 \times 10^6$  cell aliquots frozen and then shipped to New York where  
181 they were stored at  $-135^\circ\text{C}$ . PBMC specimens were identified with a unique patient identifier which  
182 did not correspond to their TB status. For analysis, participants were assigned to TB and no-TB  
183 groups after laboratory assessments were complete.

184

#### 185 Intact proviral DNA assay (IPDA)

186 For each participant, one aliquot of  $5 \times 10^6$  cells was thawed and washed before CD4+ T cell  
187 isolation by negative selection (EasySep™ Human CD4+ T cell Enrichment Kit, Stem Cell  
188 Technologies). DNA was then isolated using a column-based method (DNeasy Miniprep Kit,  
189 Qiagen) and quantitated using Nanodrop (Thermo Fisher Scientific). Intact proviral DNA  
190 amplification was determined using droplet digital PCR (ddPCR) on a QX200 instrument (Bio-  
191 Rad) (4). Amplification of the HIV *gag* (*psi*) and *pol* regions and human *rpp30* were done  
192 independently in parallel with quadruple technical replicates and for DNA shearing using *rpp30*.  
193 PCR reactions with fewer than 10,000 droplets read were excluded from the calculation for that  
194 participant. Participants who did not have any detectable *env* or *psi* amplification using the primers  
195 and conditions described in Bruner et al (4) and Gunst et al (8) were re-run with secondary *env*  
196 primers and probes as described in Kinloch et al (5). Participants with no amplifiable HIV DNA  
197 (*gag* fragment and *psi* fragment) with both primer sets were also excluded (n=1). From the  
198 ddPCR, we generated numbers of 3' defective (*env*), 5' defective (*psi*), and presumed intact  
199 provirus containing both *env* and *psi* per million CD4+ T cells.



200

201 HIV viral load

202 Blood from participants in the pilot TBRU study were collected with heparin as the anticoagulant,  
203 so viral load results were not reliable. Instead, we tested plasma for HIV circulating p24 gag  
204 protein using an ELISA (RETRO-TEK™ HIV-1 p24 Antigen ELISA, ZeptoMetrix, Buffalo, NY) with  
205 immune dissociation and reactive confirmation (HIV-1 p24 ICx/CRx kit, ZeptoMetrix). Participants  
206 who had detectable p24 or who did not have plasma available for p24 testing were excluded from  
207 final analysis of the pilot cohort.

208

209 Participants in the TB recurrence study were to have had undetectable viral loads prior to  
210 enrollment in the study. However, because of the impact that active HIV replication could have on  
211 the IPDA, we measured p24 in these participants as well using plasma collected with EDTA  
212 anticoagulant. Plasma was centrifuged at 10,000 xg for 10 minutes to remove particulates. RNA  
213 was extracted from plasma using a semi-automated method and HIV viral load quantitated using  
214 a previously described integrase single copy assay (9, 10). Participants who had viral load > 1,000  
215 copies/mL and detectable p24 after immune dissociation and neutralization were excluded.  
216 Samples were analyzed on an ABI Vii7 Real-Time PCR System. Cycle threshold values were  
217 compared with a validated HIV RNA standard run to determine concentration.

218

219 Cytokine levels

220 Plasma levels of granulocyte-macrophage colony-stimulating factor, interferon gamma,  
221 interleukin 1 beta (IL1B), interleukin 2 (IL2), interleukin 4 (IL4), interleukin 5 (IL5), interleukin 6  
222 (IL6), interleukin 12p70 (IL12p70), interleukin 13 (IL13), interleukin 18 (IL18), and tumor necrosis  
223 factor (TNF) were measured using a bead-based multiplex assay (Th1/Th2 11-plex Human  
224 ProcartaPlex Panel, Invitrogen). Quantitation was performed using a Luminex MAGPIX system  
225 with xPONENT v4.3 software (Luminex, Austin, TX) according to the manufacturer's instructions

226 with the following specifications. Plasma was spun at 10,000 xg for 10 minutes to remove  
227 particulates prior to aliquoting onto the plate. Incubation was overnight at room temperature. All  
228 samples were run in duplicate and the average reading used for quantitation with the standard  
229 curve. For samples that were less than the lower limit of detection, we imputed a value of half the  
230 difference between zero and the lowest concentration standard on the standard curve for each  
231 cytokine. Cytokines that were less than the level of detection for more than 50% of plasma  
232 samples did not continue to statistical analyses.

233

#### 234 Data and Statistical analysis

235 Demographic and clinical characteristics were expressed as numbers and percentages with  
236 interquartile range given for continuous variables. All statistical analysis was done in Stata  
237 (version 18, College Station, TX, USA). Distributions of variables were tested using  
238 Skewness/Kurtosis tests for normality. For normality test  $p < 0.05$ , Kruskal Wallis tests were used  
239 to compare medians and for normality test  $p > 0.05$ , two-sided t-tests were used for comparison  
240 of means. For proviral loads reported by IPDA as being less than the lower detection level, we  
241 input a level of 1 copy per million CD4 for two reasons: 1) the fact that these participants have un-  
242 cured HIV means that their level can't be zero and 2) we analyzed proviral loads using  $\log_{10}$   
243 because of the large numerical distribution of proviral loads and  $\log_{10}0$  is undefined whereas  
244  $\log_{10}1$  is zero. When there were a large number of undetectable ( $\log_{10}1=0$ ) proviral loads, we  
245 utilized tobit regression for left censoring of proviral loads that were less than the lower limit of  
246 detection with the IPDA (11). After completing the Luminex plasma cytokine assay, we excluded  
247 cytokines for which more than half of participants had a level less than the lower limit of detection.  
248 We applied Bonferroni correction for multiple analyses using the remaining number of cytokines  
249 as the correction factor. We used Pearson's correlation coefficient (<pwcorr> in Stata) to compare  
250 quantities of provirus and cytokines. For all analyses, the cutoff for significance was  $p \leq 0.05$ .

251

252 For a post-hoc analysis, we compared the rates of usage of alternative primers in the IPDA to  
253 determine if differences in proviral loads between TB and non-TB groups were related to use of  
254 different primer sets. The rates of primer usage by group are included in Supplemental Tables 1,  
255 2, and 3. For the first cohort, where there was a statistically significant difference in use of  
256 alternate primers between the groups, we stratified by primer type and compared log intact  
257 proviral load between TB groups separately in those samples amplified by original IPDA primers  
258 ( $p=0.0012$ ) and those samples amplified by alternate primers ( $p=0.016$ ).

259

#### 260 Study approval

261 This study was approved by institutional review boards at Weill Cornell Medicine and GHESKIO  
262 Centers. Study participants provided written informed consent. All participants were offered  
263 antiretroviral and anti-TB treatment and continuing care for HIV and TB per the Haitian national  
264 guidelines and the GHESKIO standard of care.

265

#### 266 Data availability

267 The data used to generate the figures and supplemental figures are included in the Supporting  
268 Data Values document. Additional information is available from the authors upon reasonable  
269 request.

270

## 271 **2. Financial Contributions**

272 The authors recognize funding to KD (NIH K23-AI131913 and R01-AI176943, Doris Duke  
273 Charitable Foundation Clinical Scientist Development Award) and DWF (NIH U19-AI111143,  
274 P30-AI168433, and K24-AI098627). Additionally, this project utilized databases maintained in  
275 REDCap, supported by UL1-TR002385 from the National Center for Advancing Translational  
276 Sciences of the NIH. We acknowledge the patient care, clinical research, and laboratory teams  
277 at GHESKIO Centers in Port au Prince, Haiti.

278

279 **3. Supplemental references**

280 7. WHO. Tuberculosis profile: Haiti.

281 8. Gunst JD, Pahus MH, Rosas-Umbert M, Lu IN, Benfield T, Nielsen H, et al. Early  
282 intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with  
283 HIV-1: a phase 1b/2a, randomized trial. *Nat Med.* 2022;28(11):2424-35.

284 9. Cillo AR, Vagratian D, Bedison MA, Anderson EM, Kearney MF, Fyne E, et al. Improved  
285 single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive  
286 antiretroviral therapy. *J Clin Microbiol.* 2014;52(11):3944-51.

287 10. McCann CD, van Dorp CH, Danesh A, Ward AR, Dilling TR, Mota TM, et al. A  
288 participant-derived xenograft model of HIV enables long-term evaluation of autologous  
289 immunotherapies. *J Exp Med.* 2021;218(7).

290 11. Tobin J. Estimation of Relationships for Limited Dependent-Variables. *Econometrica.*  
291 1958;26(1):24-36.

292

293 **4. Author Contributions**

294 MAJJ\*- clinical studies (TBRU – pilot cohort), acquire data

295 YJ\* - clinical studies (TB recurrence – confirmatory cohort), acquire data

296 DL – clinical studies (TB recurrence – confirmatory cohort), acquire data

297 AA – technical expertise

298 PJ - conduct experiments, write manuscript

299 MHL – analyze data

300 MW – conduct experiments, acquire data

301 EB- conduct experiments, acquire data

302 YD- conduct experiments, acquire data

303 UC - conduct experiments, acquire data

- 304 AD– conduct experiments, acquire data
- 305 WCA– conduct experiments, acquire data
- 306 DWF – design research studies, data interpretation
- 307 JWP – design research studies
- 308 RBJ– design research studies, analyze data, data interpretation
- 309 KMD – design research studies, conduct experiments, acquire data, analyze data, data
- 310 interpretation, write manuscript

311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336

## REFERENCES

### **Main References**

1. de Oliveira MF, Murrell B, Perez-Santiago J, Vargas M, Ellis RJ, Letendre S, et al. Circulating HIV DNA Correlates With Neurocognitive Impairment in Older HIV-infected Adults on Suppressing ART. *Sci Rep.* 2015;5:17094.
2. Olson A, Ragan EJ, Nakiyingi L, Lin N, Jacobson KR, Ellner JJ, et al. Brief Report: Pulmonary Tuberculosis Is Associated With Persistent Systemic Inflammation and Decreased HIV-1 Reservoir Markers in Coinfected Ugandans. *J Acquir Immune Defic Syndr.* 2018;79(3):407-11.
3. Xun J, Qi T, Zou L, Tang Q, Shen Y, Yang J, et al. Mycobacterium tuberculosis co-infection is associated with increased surrogate marker of the HIV reservoir. *AIDS Res Ther.* 2020;17(1):63.
4. Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. *Nature.* 2019;566(7742):120-5.
5. Kinloch NN, Ren Y, Conce Alberto WD, Dong W, Khadka P, Huang SH, et al. HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). *Nat Commun.* 2021;12(1):165.
6. Waters R, Ndengane M, Abrahams M, Diedrich C, Wilkinson R, Coussens A. The Mtb-HIV syndemic interaction: why treating M. tuberculosis infection may be crucial for HIV-1 eradication. *Future Virology.* 2020;15(2):101-25.

### **Supplemental References**

7. WHO. Tuberculosis profile: Haiti.
8. Gunst JD, Pahus MH, Rosas-Umbert M, Lu IN, Benfield T, Nielsen H, et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial. *Nat Med.* 2022;28(11):2424-35.

- 337 9. Cillo AR, Vagratan D, Bedison MA, Anderson EM, Kearney MF, Fyne E, et al. Improved  
338 single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive  
339 antiretroviral therapy. *J Clin Microbiol.* 2014;52(11):3944-51.
- 340 10. McCann CD, van Dorp CH, Danesh A, Ward AR, Dilling TR, Mota TM, et al. A  
341 participant-derived xenograft model of HIV enables long-term evaluation of autologous  
342 immunotherapies. *J Exp Med.* 2021;218(7).
- 343 11. Tobin J. Estimation of Relationships for Limited Dependent-Variables. *Econometrica.*  
344 1958;26(1):24-36.
- 345
- 346

347 **Figure Legends:**

348 Figure 1. There was approximately 8-fold higher circulating CD4 T cells with intact HIV provirus  
349 in PLHIV with TB or TB history compared with no history of TB ( $p=0.0001$ , 1A). This was also  
350 found in a confirmatory cohort ( $p=0.03$ , 1B). In the confirmatory cohort, plasma IL1B (1C) and  
351 IL2 (1D) levels correlated with circulating CD4 T cells containing HIV gag and/or pol ( $p=0.0025$   
352 and  $p=0.0002$ , respectively).

353

354 Supplemental Figure 1. Subgroup analysis in the full pilot cohort of intact proviral load in  
355 circulating CD4 T cells. There was no statistically significant difference between intact provirus  
356 levels for people with active vs treated pulmonary TB disease ( $p=0.92$ , S1A) or by IGRA  
357 positivity in people with no history of active pulmonary TB ( $p=0.96$ , S1B). Red pluses are the  
358 medians.

359

360 Supplemental Figure 2. There was no statistically significant difference in intact provirus in  
361 people without TB with different IGRA status at the time of study enrollment (S2A). There was  
362 also no statistically significant difference in intact provirus in people with TB history with  
363 recurrent vs only one episode of TB (S2B). Red pluses are the medians.

364



	TB group (n=50)		No TB group (n=50)	
	Untreated TB (n=25)	History of TB or on treatment (n=25)	IGRA-positive (n=25)	IGRA-negative (n=25)
Sex (#female (%))	10 (40%)	14 (56%)	16 (64%)	17 (68%)
Age in years (mean +/- SD)	38.16 +/- 7.5	38.8 +/- 6.8	44 +/- 5.9	44 +/- 4.3
Time since HIV dx in years (median (IQR))	0.02 (0.02- 0.03)	3.1 (1.1-5.4)	12.8 (11.7- 14.3)	11 (10.5-14.7)
Time on ART in years (median (IQR))	0	2.9 (0.9-4.5)	10 (8.7-10.7)	8.9 (8-10.2)
Time between diagnosis and ART (median (IQR))	.06 (0.02- 0.07)	0.9 (0.4-.57)	2.7 (2.3-4.1)	2.6 (1.3-4.7)
Alternate IPDA primers used (number (%))	7 (28%)	9 (36%)	4 (16%)	3 (12%)

365 Supplemental Table 1. Demographics of the pilot cohort

366


367

	TB group (n=18)	No TB group (n=13)
Sex (#female (%))	10 (55%)	7 (54%)
Age (mean +/- SD)	44 +/- 10.1	43.3 +/- 12.1
Time since HIV dx in years (median (IQR))	6.7 (5.4, 7.8)	6.4 (4.7, 7.9)
Time on ART in years (median (IQR))	6.2 (4.1, 7)	5 (4, 6.5)
Time between diagnosis and ART (median (IQR))	0.1 (0, 0.2)	0.8 (0, 1.6)
HIV viral load (median, (IQR))	0 (0-518)	0 (0-77)
Alternate IPDA primers used (number (%))	4 (22.2%)	3 (23%)



369  
370

Supplemental Table 2. Demographics of the final analyzed group in the confirmatory cohort

Figure 1. There was approximately 8-fold higher circulating CD4 T cells with intact HIV provirus in PLHIV with TB or TB history compared with no history of TB ( $p=0.0001$ , 1A). This was also found in a confirmatory cohort ( $p=0.03$ , 1B). In the confirmatory cohort, plasma IL1B (1C) and IL2 (1D) levels correlated with circulating CD4 T cells containing HIV gag and/or pol ( $p=0.0025$  and  $p=0.0002$ , respectively)



Supplemental Figure 1. Subgroup analysis in the full pilot cohort of intact proviral load in circulating CD4 T cells. There was no statistically significant difference between intact provirus levels for people with active vs treated pulmonary TB disease ( $p=0.92$ , S1A) or by IGRA positivity in people with no history of active pulmonary TB ( $p=0.96$ , S1B). Red pluses are the medians.



Supplemental Figure 2. There was no statistically significant difference in intact provirus in people without TB with different IGRA status at the time of study enrollment (S2A). There was also no statistically significant difference in intact provirus in people with TB history with recurrent vs only one episode of TB (S2B). Red crosses are the medians.

